Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 11,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease, Chronic Clear all
Not listed Early Phase 1 Interventional

Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury

NCT03167138
View directory record Official record
Conditions
Shoulder Pain, Shoulder Impingement Syndrome, Rotator Cuff Impingement Syndrome, Rotator Cuff Tendinitis, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Spinal Cord Injuries
Interventions
Autologous micro-fragmented adipose tissue, Lipogems system
Biological · Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn Phase 4 Interventional

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy

NCT01386255
View directory record Official record
Conditions
Cerebral Palsy, GERD
Interventions
Baclofen, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Sep 30, 2026, 9:08 AM EDT
Not yet recruiting Not applicable Interventional

Measuring Pelvic Floor Muscle Fitness Before and After Treatment

NCT07605598
View directory record Official record
Conditions
Myofacial Pain, Pelvic Pain, Myofascial Pelvic Pain, Chronic Pelvic Pain
Interventions
Near Infrared Imaging
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

TARGTEPO Treatment for Anemia in PD US Trial

NCT02468414
View directory record Official record
Conditions
Anemia of End Stage Renal Disease
Interventions
MDGN201 TARGTEPO
Biological
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn No phase listed Observational

B-Cell Hematologic Malignancy Vaccination Registry

NCT02298816
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ischemic Nerve Block to Improve Hand Function in Stroke Patients

NCT00056706
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Transient deafferentation
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting No phase listed Observational

Vascular Lab Resource (VLR) Biorepository

NCT05628948
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT07498335
View directory record Official record
Conditions
Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Interventions
Drug: Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Clobetasol for Oral Graft-Versus-Host Disease

NCT01557517
View directory record Official record
Conditions
Oral Chronic Graft vs Host Disease
Interventions
Clobetasol Oral Rinse, Placebo oral rinse
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

Chronic Evaluation of Novel Pacemaker System

NCT06056817
View directory record Official record
Conditions
Ventricular Pacing With Rate Response, Bradycardia
Interventions
Calyan Pacemaker
Device
Lead sponsor
Calyan Technologies
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Quality by Maintaining Accurate Problems in the EHR

NCT02596087
View directory record Official record
Conditions
Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions
Problem List Suggestion
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 30, 2026, 9:08 AM EDT
Not listed No phase listed Observational

The QUALITY Vets Project: Muscle Quality and Kidney Disease

NCT03160326
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 84 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

NCT00120835
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, pegylated interferon
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Timeline
Started 2004
U.S. locations
2
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Assessment of Plant-based Program Using Shared Medical Appointment

NCT05889715
View directory record Official record
Conditions
Chronic Disease, Nutrition, Healthy
Interventions
Green Wellness Program: Plants-2-Plate
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
RP-3500, Olaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Not listed Not applicable Interventional

The Prescriptive Validity of a Novel Fall Risk Clinical Prediction Rule for People With COPD

NCT05173532
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Balance Training, Breathing and Stretching Exercises
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
60 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Houston, Texas • Sugar Land, Texas • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2Phase 3 Interventional

Acupressure for Persistent Cancer Related Fatigue

NCT01281904
View directory record Official record
Conditions
Chronic Fatigue, Breast Cancer, Sleepiness
Interventions
Relaxation Acupressure, Stimulating Acupressure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional

Behavioral Intervention and Adherence in Dialysis

NCT01066949
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Behavioral self mangement, Support and discussion
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Dubuque, Iowa • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

NCT01075425
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
Interventions
bortezomib, belinostat, laboratory biomarker analysis, western blotting, pharmacological study, flow cytometry
Drug · Other · Genetic
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

NCT01525615
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525
View directory record Official record
Conditions
Hepatitis C
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Sarasota, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Sep 30, 2026, 9:08 AM EDT